Comparative trial of SGLT2-inhibitor (Canagliflozin) and sulfonylurea (Glimepiride) for patients with DM

Comparative trial of SGLT2-inhibitor (Canagliflozin) and sulfonylurea (Glimepiride) for patients with DM - Comparative trial of SGLT2-inhibitor (Canagliflozin) and sulfonylurea (Glimepiride) for patients with DM

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000024922

Enrollment

Registered

2016-11-21

Start date

2016-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes mellitus type 2

Interventions

SGLT2-inhibitor (Canagliflozin) 100mg/day, one year sulfonylurea ((Glimepiride) ) 2~6mg/day, one year

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Diabetes mellitus type 2 Patients from whom informed consent was obtained

Exclusion criteria

Exclusion criteria: Patients who were deemed not appropriate to participate in this study by doctor

Design outcomes

Primary

Measure	Time frame
somatic fat volume (CT)	—

Secondary

Measure	Time frame
HbA1c Body weight, body fat percentage somatic fat volume (CT) BNP serum Cr,eGFR glycoalbumin U-alb, U-type IV collagen cystatin C, ox-LDL, Lp (a), EPA/AA T-cho,LDL,HDL.TG Bood pressure FMD, ABI, PWV complication	—

Countries

Japan

Contacts

Public ContactAkira Sezai

Nihon University School of Medicine Department of Cardiovascular Surgery

asezai.med@gmail.com03-3972-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026